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Fragile X syndrome (FXS) patients carry the expansion of over 200 CGG repeats at the promoter of fragile X mental retardation 1
(FMR1), leading to decreased or absent expression of its encoded fragile Xmental retardation protein (FMRP). However, the global
transcriptional alteration by FMRP deficiency has not been well characterized at single nucleotide resolution, i.e., RNA-seq. Here,
we performed in-vitro neuronal differentiation of human induced pluripotent stem (iPS) cells that were derived from fibroblasts of
a FXS patient (FXS-iPSC).We then performed RNA-seq and examined the transcriptional misregulation at each intermediate stage
during in-vitro differentiation of FXS-iPSC into neurons. After thoroughly analyzing the transcriptomic data and integrating them
with those from other platforms, we found up-regulation of many genes encoding TFs for neuronal differentiation (WNT1, BMP4,
POU3F4, TFAP2C, and PAX3), down-regulation of potassium channels (KCNA1, KCNC3, KCNG2, KCNIP4, KCNJ3, KCNK9,
and KCNT1) and altered temporal regulation of SHANK1 and NNAT in FXS-iPSC derived neurons, indicating impaired neuronal
differentiation and function in FXS patients. In conclusion, we demonstrated that the FMRP deficiency in FXS patients has
significant impact on the gene expression patterns during development, which will help to discover potential targeting candidates
for the cure of FXS symptoms.
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INTRODUCTION
Fragile X syndrome (FXS) is a common hereditary disor-
der associated with an array of intellectual limitations and
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emotional disabilities, and is also referred to as the most
frequent monogenic cause of autism. In FXS patients, the
CGG repeats at the 5′ untranslated region (5′ UTR) of fragile
X mental retardation 1 (FMR1) are dramatically increased
(>200) compared to the healthy individuals. This trinu-
cleotide expansion results in many epigenetic alterations
including DNA hypermethylation and histone modifications,
which ultimately silences the expression of FMR1 (Bagni
et al., 2012). Fragile X mental retardation protein (FMRP),
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encoded by FMR1, is ubiquitously expressed in many tissues,
especially abundant in brain and testes (Devys et al., 1993).
In the nervous system, loss of FMRP elevates the protein
synthesis in the brain (Laggerbauer et al., 2001; Qin et al.,
2005), weakens the synaptic strength and affects dendritic
spines (Cruz-Martin et al., 2010; Pan et al., 2010; Pfeiffer
and Huber, 2007), which therefore affects many different
pathways, e.g., impairing metabotropic glutamate receptor
(mGluR)-mediated signaling (Bear et al., 2004) , reducing
GABAergic transmission (D’Hulst and Kooy, 2007) and en-
hancing mTOR signaling (Sharma et al., 2010). The function
of FMRP in cytoplasm was well characterized as a selective
RNA-binding protein that negatively regulates the translation
of the target mRNAs for presynaptic, postsynaptic proteins,
and interestingly, many transcriptional factors (Ascano et al.,
2012; Auerbach et al., 2011; Darnell et al., 2011; Kao et al.,
2010; Lu et al., 2004; Muddashetty et al., 2007; Osterweil et
al., 2010; Pfeiffer and Huber, 2007). FMRP also comprises
the nuclear export signal (NES) and nuclear localization
signal (NLS) domains and shuttles between the nucleus and
cytoplasm (Eberhart et al., 1996; Feng et al., 1997; Sittler et
al., 1996). Since it functions as a chromatin-binding protein
responding to the DNA damage (Alpatov et al., 2014), it is
very likely that FMRP may directly modulate the transcrip-
tion in the nucleus. Although some microarray-based gene
expression profiling data were generated from Fmr1 null
mice (D’Agata et al., 2002), FXS patients’ lymphoblastoid
cells (Bittel et al., 2007), and FXS patient derived iPS cells
(Halevy et al., 2015), RNA-seq with higher throughput and
resolution is urgently needed to dissect the transcriptional
perturbation evoked by FMRP deficiency.
Several animal models have been created to study FXS.
Fmr1 null mouse is one of the most successful mammalian
models recapitulating the phenotypes of human FXS patients,
such as abnormalities in synaptogenesis, synaptic structures
and functions (The Dutch-Belgian Fragile X Consorthium,
1994). Of particular interest, researchers also generated the
mouse model that carries specific mutation found in human
FXS patients, i.e. I340N (Zang et al., 2009). Fruitful ge-
netic rescue efficacy has been achieved in mouse models by
targeting key molecules in different pathways, i.e., mGluR
(Dolen et al., 2007; Lindemann et al., 2011; Michalon et
al., 2012), amyloid β-protein precursor (AβPP) (Westmark et
al., 2011), mTOR (Auerbach et al., 2011), p21-activated ki-
nase (PAK) (Hayashi et al., 2007), and protein tyrosine phos-
phatase (STEP) (Goebel-Goody et al., 2012). However, the
mouse models have obvious limitations. For example, the
transgenic mice do not carry the trinucleotide expansion. Un-
controllable variations such as age and genetic background
influence the interpretation of different experimental settings.
Recent progress in FXS human embryonic stem (ES) cells
and iPS cells has overcome the drawbacks of the mouse mod-
els, which offers us a great tool to understand the pathogenic
mechanisms in absence of FMRP (Eiges et al., 2007; Huang
and Fu, 2014; Sheridan et al., 2011; Telias et al., 2013; Wu et
al., 2007).
As stated above, the aberrant developmental phenotypes in
FXS patients may be partly caused by a global disturbance
of transcriptional regulation due to FMRP deficiency, which
still remains unknown yet. To test this hypothesis, we ob-
tained and examined a FXS-iPSC cell line (a kind gift from
Dr. Philip H. Schwartz) from the fibroblasts of a FXS patient
with expanded CGG repeats on the FMR1 promoter (Brick
et al., 2014). We then differentiated FXS-iPSC, along with a
healthy iPS cell line HDF2-iPSC as control, into post-mitotic
neurons through different stages, i.e., iPSC aggregates (IA),
neuroepithelia (NE), neuroepithelia aggregates (NA). After
analyzing total 200 million mapped reads of RNA-seq data
from the RNA collected at 4 different stages for each cell line,
we found total 1,559 differentially expressed (DE) genes be-
tween FXS-iPSC and HDF2-iPSC during the neuronal differ-
entiation. At the neuron stage, the genes related to early neu-
ronal differentiation (e.g., WNT1, BMP4, and POU3F4) are
up-regulated while many genes essential for neuronal func-
tions such as potassium channels (KCNA1, KCNC3, KCNG2,
KCNIP4, KCNJ3, KCNK9, and KCNT1) are down-regulated,
which implied that FXS-iPSC derived neurons are immature
and have impaired function compared to the mature neurons.
In addition, we discovered the disruption of spatiotemporal
regulation of some important neuronal factors, i.e., SHANK1
and NNAT. Our study, for the first time, revealed the altered
transcriptome in patient-derived FXS-iPSC at different de-
velopmental stages by high-throughput RNA-seq, which will
lead to recognition of the function of FMRP in direct/indi-
rect transcriptional regulation. The genes which we charac-
terized as important for neuronal differentiation and develop-
ment will aid in the discovery of novel therapeutics for FXS
in the future.
RESULTS
Neuronal differentiation of FXS-iPSC
We obtained a FXS-iPSC cell line (named SC128) from Dr.
Philip H. Schwartz at Children’s Hospital of Orange County,
USA (Brick et al., 2014). This cell line has been stably and
homogenously expanded for over 28 passages and kept main-
taining ESC-like morphology (data not shown). All iPSC
clones had typical characteristics of human pluripotent stem
cells indicating successful reprogramming (data not shown).
Using Asuragen Amplide X FMR1 PCR Kit, we found that
there are 236 CGG repeats at the 5′ UTR of FMR1 in FXS-
iPSC, whereas 36 in the control HDF2-iPSC (Figure S1A and
B in Supporting Information). The expression of FMRP was
not detected in the FXS-iPSC compared to the WT control
HDF2-iPSC (Figure 1B, Figure S1C in Supporting Informa-
tion).
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Figure 1   In-vitro differentiation of FXS-iPSC into neurons. A, The diagram of the neural differentiation process. B–D, Immunostaining of the cells using
antibodies against FMRP, and pluripotent markers NANOG and SOX2 at iPSC stage (B); against neural epithelia cell markers NESTIN, SOX1, and PAX6 at
NE stage (C), and against neuron markers MAP2 and TUJ1 at NU stage (D). iPSC, induced pluripotent cell; NE, neuroepithelia; NU, neuron.
We then performed a step-wise in-vitro differentiation of
FXS-iPSC into neurons (Figure 1A). During the in-vitro
differentiation process, we found that FXS-iPSC and its
derived cells at different stages express the correct markers
as does the control HDF2-iPSC, although FMRP expression
was barely detected by fluorescence immunostaining (Figure
1B–D) and real-time RT-PCR (Figure S1C in Supporting
Information). However, we noticed that neurons differenti-
ated from FXS-iPSC are significantly fewer than those from
HDF2-iPSC (73.2%±0.8% vs. 83.7%±3.9%, P=0.0019),
which was consistent with the previous findings in FXS
patient derived ESCs (Telias et al., 2013).
FMRP deficiency results in altered gene expression pat-
tern during neurogenesis
To test our hypothesis weather the gene expression profile is
changed by FMRP deficiency, we collected the RNA sam-
ples at four developmental stages during in-vitro differen-
tiation, i.e., 0-day (D0, iPSC stage), 6-day (D6, IA stage),
18-day (D18, NA stage) and 50-day (D50, neuron stage).
We constructed the Tru-seq libraries following the manufac-
turer’s protocol. After RNA-seq on the Illumina Hi-seq plat-
form, we retrieved approximately 200 million mapped reads
from the total 8 samples of FXS-iPSC and HDF2-iPSC. Af-
ter performing unsupervised hierarchal clustering and princi-
pal component analysis (PCA), we found that FXS-iPSC and
its derived cells share very similar gene expression patterns
with HDF2-iPSC and its derived cells when given a certain
stage respectively (Figure 2A and B). To validate our in-vitro
differentiation method, we compared the transcriptomic pro-
files with the single-cell data at different stages by Pasca et
al. (Pasca et al., 2011). We found that the expression pat-
terns of our cell lines at early stages, i.e., D0 and D6, cluster
closely with the other group’s iPSC stage, whereas those at
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D18 and D50 match their neurosphere and neuron stages re-
spectively (Figure 2C), which indicated that bothHDF2-iPSC
and FXS-iPSC were successfully differentiated into neurons.
Taken together, FMRP deficiency results in subtle transcrip-
tion perturbation, as regard to the affected genes and their
mRNA level, and FXS-iPSC is capable of being differenti-
ated into neurons morphologically similar to those derived
from the control HDF2-iPSC.
We used the threshold of P<0.05 and log2 (fold change)
>1 and found totally 1,559 differentially-expressed genes
(DEGs) between FXS-iPSC and HDF2-iPSC by pairwise
comparison during the whole neuron differentiation process
(Figure 2D, Table S1 in Supporting Information). Most of
the DEGs are at iPSC stage, and DEGs on D6 and D18 have
Figure 2   The gene expression pattern of FXS-iPSC during neurogenesis. A, Unsupervised hierarchical clustering of gene expression profiles well defines
known phases of neurogenesis. B, Principal component analysis (PCA) of gene expression profiles at defined time points from both HDF and SC128 samples.
C, Clustering of gene expression profile revealed similar patterns in neuronal differentiation as previously reported by Pasca et al. in 2011. D, Volcano plot
shows an overall comparison of HDF and SC128 samples. log2 FC indicates log2 scaled fold change of gene expression in SC128 vs. HDF.
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a relatively high overlapwith those on the other stages (Figure
S2 in Supporting Information). Interestingly, GO analysis
of the DEGs showed that up- and down-regulated genes in
FXS-iPSC and its derived cells belong to different categories
related to embryonic morphogenesis, neuronal differentiation
and function, which underscores the fundamental defects in
the transcriptional regulation during neuronal differentiation
and will be further examined as follows.
The gene expression profiles are consistent with those in
the previous in-vitro differentiation of FXS-iPSC
Due to the batch effect and genetic variation in different
FXS patients, we next asked whether and how well the gene
expression profiles from one FXS patient-derived cell line
(FXS-iPSC) and its control (HDF2-iPSC) can be generalized
to explain the transcriptional alteration during neurogenesis
in FXS patients. After literature search, we found a set of
transcriptome data generated from FXS patient-derived iPS
cells and their derived neurons (Halevy et al., 2015), which
perfectly matched our work except that their data were gen-
erated by microarray and only collected at iPSC and neuron
stages. In general, our data are in consistent with those from
Halevy et al. (Halevy et al., 2015). As shown in Figure 3A
and B, our RNA-seq data on D0 and D50 arerespectively
clustered together with iPSCs and neurons in Halevy’s data,
but far away from WT and FXS fibroblasts, indicating that
the quality of our in-vitro differentiation and RNA-seq is
high. Since the data from Halevy et al. do not include inter-
Figure 3   Integrated analysis of our RNA-seq data and those in the previous in-vitro differentiation of FXS-iPSCs. A, Heatmap shows hierarchical clustering
of correlation between gene expression from our RNA-seq data and the microarray data (Halevy et al., 2015). Our samples are named HDF and SC128, whereas
the samples from Halevy et al. are named WT and FXS. B, PCA of gene expression profiles shows the samples in the present work and the other group’s work
(Halevy et al., 2015) cluster at iPSC and neuron stages respectively. C, Number of DEGs at neuron stage found in our and Halevy’s data. Up stands for genes
up-regulated in FXS sample. Down stands for genes down-regulated in FXS sample.
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mediate stages during in-vitro differentiation, all our data on
D0, D6 and D18 cluster with the iPSCs instead. We also no-
ticed that our data cluster closely with each other, however
those of Halevy et al. show more variation among different
samples. Nevertheless, the data from both groups can detect a
number of up-regulated and down-regulated DEGs at neuron
stage (Figure 3C), which will be discussed in the following
sections. In conclusion, our data are representative expres-
sion profiles during neurogenesis in FXS patients and can be
further analyzed by combining other data from different plat-
forms.
Distinctive gene expression patterns at neuron stage de-
termine the phenotypic difference in neuronal differenti-
ation between FXS-iPSC and HDF2-iPSC
We next investigated the altered gene expression patterns in
FXS-iPSC at neuron stage. Heatmap of log2 fold change
showed two distinct clusters of neuron-specific (D50) DEGs
(Figure 4A). Cluster 1 is composed of up-regulated genes
(Figure 4A and B), while cluster 2 has all the down-regulated
genes (Figure 4A and D). Interestingly, up- and down- regu-
lated genes of FXS-iPSC at neuron stage are associated with
functions including embryonic morphogenesis and synaptic
transmission. As the final consequence of FMRP deficiency,
the DEGs in this group may eventually reflect the perturba-
tion of global transcription and thus lead to functional defects
during neurogenesis. As shown in Table 1, we found some
neurogenesis related genes in Cluster 1, e.g., WNT1, BMP4,
POU3F4, TFAP2C and PAX3, suggesting that FXS-iPSC de-
rived neurons are relatively immature. Interestingly, many
genes in Cluster 2 encode potassium channels, e.g., KCNA1,
KCNC3, KCNG2, KCNIP4, KCNJ3, KCNK9, and KCNT1,
whose down-regulation may cause neuronal defects in FXS
patients. We validated the expression patterns of some genes
by real-time RT-PCR (Figure 4A). Furthermore, the gene ex-
pression patterns in these two clusters are confirmed by com-
Figure 4   Four clusters of genes up- or down-regulated at neuron stage. A, Heatmap of log2 fold change (SC128/HDF) at different developmental stages
reveals four clusters of genes either up- or down-regulated on D50. GO analysis indicated the biological functions of genes in each cluster. The mRNA level
of representative genes in each cluster was validated by real-time RT-PCR. B, Boxplot shows up-regulation of genes in GO term “embryonic morphogenesis”
(GO:0048598) in our RNA-seq data. C, The genes with the same GO term as in B (GO:0048598) are also up-regulated in Halevy’s microarray data. D, Boxplot
shows down-regulation of 79 potassium related genes (defined by HGNC) in our RNA-seq data. E, The same group of potassium related genes as in D is also
down-regulated in Halevy’s microarray data. The values of expression level were log2-transformed. P values were calculated by paired t-test.
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parison of our datawith those in the previous report byHalevy
et al. (Halevy et al., 2015). For example, genes in GO term
“embryonic morphogenesis” (GO:0048598) are significantly
up-regulated (Figure 4B and C), and those encoding potas-
sium channels are significantly down-regulated (Figure 4D
and E).
By contrast, there are also some genes in FXS-iPSC ei-
ther down-regulated (Cluster 3) or up-regulated (Cluster 4)
throughout the entire in-vitro neuronal differentiation, which
execute important functions related to the development
of nervous system (Figure 4A). We performed real-time
RT-PCR (Figure 4A) and found that the temporal expression
patterns of SHANK1 in Cluster 3 and NNAT in Cluster 4 are
dramatically altered as referred to human brain transcriptome
(HBT), which implied that these two genes are very likely
related to intellectual disability of FXS. Finally, the biolog-
ical network analysis (Figure 5A) further demonstrated that
all these DEGs (Table 1) are in the central axes of neuronal
functions and their combinatory regulation is essential for
the mature neurons.
Figure 5   FMRP regulates the transcription of certain genes in the nucleus during neurogenesis. A, The biological function networks are diagramed using
GeneMANIA, which show that the cooperation of DEGs is essential for neural development and function. The big circle highlight up- (red) and down- (blue)
regulated DEGs found at the neuron stage (D50) in our work. The yellow diamonds in the center represent the major biological functions, i.e., neural develop-
ment, potassium channels and glutamatergic synapse. The colored lines connect the biological function to each DEG respectively. B, The diagram shows that
the transcription of different groups of genes during neuronal differentiation is positively (indicated by “+”) or negatively (indicated by “–”) regulated by either
the transcription factors whose translation is inhibited by FMRP, and/or nucleus-localized FMRP. However, it still needs to be elucidated how small amount of
FMRP (5%) is transported into nucleus (indicated by the question mark) and how it interacts with other unknown factors (indicated by the question mark) to
regulate the transcription directly and/or indirectly.
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Table 1    Candidate genes misregulated in FXS-iPSC during in-vitro differentiation
Symbol Description Location Cluster Function
WNT1 wingless-type MMTV integration site family member 1 12q13 3 GO:0007399~nervous system development
BMP4 bone morphogenetic protein 4 14q22-q23 3 GO:0030154~cell differentiation
POU3F4 POU class 3 homeobox 4 Xq21.1 3 GO:0006357~regulation of transcription from
RNA polymerase II promoter
TFAP2C transcription factor AP-2 gamma (activating enhancer
binding protein 2 gamma)
20q13.2 3 GO:0006357~regulation of transcription from
RNA polymerase II promoter
KCNA1 potassium channel, voltage gated shaker related
subfamily A, member 1
12p13.32 4 GO:0006812~cation transport
KCNC3 potassium channel, voltage gated Shaw related
subfamily C, member 3
19q13.33 4 GO:0006812cation transport
KCNG2 potassium channel, voltage gated modifier sub-
family G, member 2
18q23 4 GO:0006812~cation transport
KCNIP4 Kv channel interacting protein 4 4p15.32 4 GO:0007600~sensory perception
KCNJ3 potassium channel, inwardly rectifying subfamily J, member 3 2q24.1 4 GO:0006812~cation transport
KCNK9 potassium channel, two pore domain subfamily K, member 9 8q24.3 4 GO:0006812~cation transport
KCNT1 potassium channel, sodium activated subfamily T, member 1 9q34.3 4 GO:0008324~cation transmembrane
transporter activity
SHANK1 SH3 and multiple ankyrin repeat domains 1 19q13.3 5 GO:2000463~positive regulation of excitatory
postsynaptic potential
NNAT neuronatin 20q11.2-q12 6 GO:0007399~nervous system development
DISCUSSION
Investigators are pursuing the question of whether and how
the transcription machinery is altered in the FXS patients
(Bittel et al., 2007; D’Agata et al., 2002; Halevy et al.,
2015), although the disturbed translation has been widely
accepted as molecular mechanism underlying FXS (Darnell
and Klann, 2013). The altered transcription can be explained
by combinatory effects. First of all, RNA binding domains of
FMRP help its recognition and translational suppression of
approximate 6,000 mRNA targets (Ascano et al., 2012), 932
of which fall into the category of known transcription factors
(TFs) (Vaquerizas et al., 2009). Thus the misregulated TFs
indirectly cause the genome-wide transcription perturbation.
Second, a small portion of FMRP resides inside nucleus, im-
plying its nuclear functions such as transcriptional regulation,
mRNA splicing and DNA damage repair. However, little
is known on its involvement in transcriptional regulation
except DNA damage repair (Alpatov et al., 2014). Lastly,
the epigenetic changes on the 5′ UTR of FMR1 promoter
expand on the neighboring regions on X chromosome, which
may affect the related gene expression patterns directly or
indirectly. Unlike the previous low-throughput microarray
data which examine the affected transcription in either Fmr1
null mouse model (D’Agata et al., 2002) or lymphoblasts
of male FXS patients (Bittel et al., 2007), we performed
in-vitro differentiation of the patient derived iPS cells into
neurons, comprehensively analyzed the expression profiling
at each developmental stage, and discovered total 1,559
DEGs whose expression levels are altered due to FMRP
deficiency. We categorized the DEGs in different patterned
clusters (Table 1) and found that many of them crosstalk to
each other and cooperate in major neuronal functions such as
neural development, potassium channels and glutamatergic
synapse (Figure 5A), which implied that their misregulation
very likely leads to the pathophysiology of FXS. By combi-
natorial analysis of the data generated by us and other groups,
we concluded that FMRP can regulate the transcription of
certain groups of genes in the nucleus during neurogenesis
(Figure 5B), however, the detailed mechanisms still need to
be elucidated in the future.
The DEGs at neuron stage (Cluster 1 and Cluster 2) are
mainly associated with neurogenesis, synaptic plasticity and
circuit excitability, which implied that their misregulation at
transcriptional level may contribute to the intellectual disor-
ders in FXS patients. Some important TFs such as WNT1,
BMP4, POU3F4, and TFAP2C are upregulated in FXS-iPSC
derived neurons. As well known, WNT and BMP signal-
ing is required to maintain the stem-cell status, and inhibi-
tion of BMP signaling pathway permits in-vitro neuronal dif-
ferentiation. Mouse Pou3f4 is involved in a regulatory net-
work for early neurogenesis activated by Pax6-BAF complex
(Ninkovic et al., 2013). In zebrafish, spatiotemporal expres-
sion of Tfap2c together with Tfap2a is required for neural
crest induction (Li and Cornell, 2007). Thus the elevated ex-
pression of these TFs is most likely an indication of premature
neurons, suggesting that the intrinsic transcriptional perturba-
tion in FXS-iPSC prevents or postpones the neuronal differ-
entiation processes. PAX3 is also found in Cluster 1, which in-
volves in neural crest induction, specification, and differenti-
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ation (Monsoro-Burq, 2015). So the high expression level of
PAX3 may break the balanced neuronal differentiation, e.g.,
increase or decrease neuron subtypes, resulting in the intellec-
tual disorders of FXS. Cluster 2 includes many genes encod-
ing potassium channels, i.e., KCNA1, KCNC3, KCNG2, KC-
NIP4, KCNJ3, KCNK9, and KCNT1, whose transcriptional
level is lower in FXS-iPSC derived neurons. Different potas-
sium channels play important roles in maintaining membrane
potential in different neurons, whose misregulation are asso-
ciated with intellectual disease such as FXS (Lee and Jan,
2012). To date, FMRP is found to modulate the function
of four potassium channels, encoded by KCNT1 (Brown et
al., 2010), KCNC1 (Strumbos et al., 2010) and KCND2 (Lee
et al., 2011) and KCNMA1 (Deng et al., 2013) respectively,
by either translational regulation or direct protein-protein in-
teraction. In line with this, our finding of down-regulated
expression of potassium channels revealed another layer of
transcriptional regulation by FMRP in controlling membrane
potential related to pathology of FXS.We found a few up-reg-
ulated (PRKCG andGRIN3A in Cluster 1) or down-regulated
(GRIN1, GRIA4, GRIN2B, GRM5 and GRM7 in Cluster 2)
DEGs in mGluR pathway. Although there is no particular
pattern that fits into the translational regulation in the mGluR
theory, we speculated that the down-regulated expression of
mGluR5 itself may be a feedback due to translational misreg-
ulation by FMRP deficiency.
The spatiotemporal transcription is precisely regulated dur-
ing neuronal development, supported by the database in HBT
(Johnson et al., 2009; Kang et al., 2011; Pletikos et al., 2014).
When we examined the clusters of genes either up- or down-
regulated throughout all the stages (Figure 4A), we found
that the temporal transcription patterns are dramatically in-
versed compared with those in HBT. For example, we found
two candidates SH3 and multiple ankyrin repeat domains 1
(SHANK1) and neuronatin (NNAT), whose misregulation are
very likely related to FXS (Figure 4A). As diagrammed in
HBT, SHANK1 expression increases and reaches the plateau
after birth. But in the FXS-iPSC derived neurons, SHANK1
mRNA level is kept low and then steeply decreased at D50.
SHANK1 encodes a synaptic scaffold protein and its muta-
tions have a strong correlationwith autism spectrum disorders
(ASD) in both patients (Sato et al., 2012; Leblond et al., 2014)
and animal models (Hung et al., 2008). Although a previ-
ous report did not find significant change of SHANK1mRNA
level in Fmr1–/– mice (Schutt et al., 2009), we argue that this
was probably due to the variation in model system and sam-
ple preparation. The function of SHANK1 in FXS pathol-
ogy should be further validated as there have been many ev-
idences of the phenotypic overlap between ASD and FXS
(Devitt et al., 2015). Compared to HBT results which show
that NNAT expression declines during neuronal development
and reaches the bottom after birth, NNAT mRNA level in
FXS-iPSC derived neurons is modestly high and spikes at
D18 and D50. NNAT, an imprinted gene expressed from
paternal allele, is down-regulated when PC12 cells undergo
neuronal differentiation (Joseph et al., 1996; Zheng et al.,
2002). Since high level of NNAT aggregates are found in
Lafora disease (Sharma et al., 2011; Sharma et al., 2013) and
phenylketonuria (Surendran et al., 2005), our data suggested
that elevated NNAT expression may hinder the neuronal de-
velopment in FXS patients.
Our results agreed on the widely-accepted fact that FXS
is caused, at least initiated, by FMR1 single gene mutation
(Bagni et al., 2012; Nelson et al., 2013). Otherwise, if DNA
methylation at the 5′ UTR of FMR1 and the subsequent
epigenetic alteration expanded and repressed the adjacent
gene expression, we should have discovered the repression of
certain genes near fragile site on X chromosome throughout
the entire neuronal differentiation. We did find the clusters
of genes which are either up-regulated or down-regulated
through iPSC to neuron stage (Figure 4A, Figure S2A and B
in Supporting Information). However, GO analysis showed
that both up- and down- regulated genes had rather low
enrichment for certain biological processes (Figure 4A).
We found 9 down-regulated genes at all stages, none of
which were on X chromosome (Figure S2C in Supporting
Information). Instead, most of them are near the telomeres
of chromosome 19, including 19p-specific zinc finger genes
(Figure S2C in Supporting Information) (Mohrenweiser
et al., 1998), i.e., ZFN558, ZFN681. Since males have
higher crossover ratio near the telomeres of chromosome
19 (Mohrenweiser et al., 1998; Tapper et al., 2005), the de-
creased expression of these genes is most likely the stochastic
alteration due to sex-specific recombination. Together,
FMR1 mutation does not directly give rise to transcriptional
repression near its locus on X chromosome.
In conclusion, we discovered the transcriptional pertur-
bation during neuronal differentiation by intensive analysis
of high-throughput RNA-seq results using in-vitro iPS cell
model. We found many candidate genes which are very
likely related to intellectual disability in FXS patients. Since
most of the genes have not yet been reported in FXS patients
or disease models, our work provided a rich resource for
both academic study on the molecular etiology of FXS and
pharmaceutical screening for new medicine of the cure.
MATERIALS AND METHODS
Animals
Pregnant CF1micewere purchased fromSlac LaboratoryAn-
imal (Shanghai) and raised in the animal facility at Tongji
University. All animal experiments were approved by Tongji
University’s Committee on Animal Care and Use (# TJMED-
013-063). The mice in static cages were kept in a 12-h light,
12-h dark cycle with ad libitum access to food and water. We
made all efforts to reduce animal suffering. To make mouse
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embryonic fibroblast (MEF), we sacrificed the pregnant mice
by cervical dislocation within a short period of about 15 s.
Cell culture
We obtained HDF2-iPSC cell line from UCLA Stem Cell
Core (Liao et al., 2010) and FXS-iPSC cell line (named
SC128) from Dr. Philip H. Schwartz at Children’s Hospital
of Orange County, USA (Brick et al., 2014). Cells were
maintained at 37°C and 5% CO2, and the media changed
every three days. For mouse embryonic fibroblast (MEF)
isolation, uteri were isolated from 13.5-day-pregnant CF1
mice and washed with phosphate-buffered saline (PBS).
The fetal head and visceral tissues were removed, and the
remaining bodies washed with fresh PBS, transferred into a
0.1 mmol L–1 trypsin/1 mmol L–1 ethylene diamine tetraacetic
acid (EDTA) solution, and incubated for 20 min. After
incubation, MEF culture medium (dulbecco’s modified eagle
medium (DMEM) containing 15% defined FBS) was added
and pipetted up and down to dissociate cells. MEFs were
used as feeders at passages one to three.
iPS cells were maintained in DMEM/F12 (Invitrogen,
USA), supplemented with 2 mmol L–1 L-glutamine (Invit-
rogen), 1 mmol L–1 β-mercaptoethanol, 1× non-essential
amino acids (NEAA, Invitrogen), 20% knock-out serum
replacement (KSR, Invitrogen), 100 U mL–1 penicillin and
100 μg mL–1 streptomycin (Invitrogen). hiPS cells were
maintained on MEF cells. For picking and passaging, hiPS
cells were washed once with ES media 3, incubated with
0.1% collagenase type IV solution (StemCell Tech, USA)
for 10 min, and then mechanically disrupted. An appropriate
volume of mediumwas added and hiPS cells were transferred
onto MEF feeder cells on a new dish. The cultures were split
at a 1:1 ratio until passage 3, and 1:4 thereafter.
In-vitro neural differentiation
We performed the in-vitro neural differentiation following
a previous described protocol (Zhang and Zhang, 2010).
iPS colonies were enzymatically lifted (CollagenaseIV,
1 mg mL–1) and grown in suspension to create floating iPS
cell aggregates (IA). IA were grown for 6 days:4 days in
DMEM:F12 (Invitrogen) containing 20% KSR (Invitrogen),
1% Glutamax (Invitrogen), 1% NEAA (Invitrogen); and
2 days in neural induction medium (NIM) composed of
DMEM:F12 (Invitrogen) containing 1% N2 (Invitrogen),
1% Glutamax (Invitrogen), 1% NEAA (Invitrogen) and
heparin (1 mg mL–1, Sigma, USA); IA were reseeded onto
laminin (20 μg mL–1, Gibco) coated 6-well plate and cul-
tured in NIM for 11 days, until they developed into the
definitive neural epithelia (NE) containing neural tube-like
rosettes. NE were detached by gentle pipetting leaving the
peripheral flat cells attached and further grown in suspension
medium (NIM supplemented with 1% B27 to create neural
epithelia aggregates (NA) for 8 days. At day 25, NA were
mechanically digested by accutase/trypsin (1:1) and plated
on glass coverslips (Fisher Scientific, USA) coated with
poly-L-ornithine/laminin (Sigma, at a final concentration
of 10 and 20 μg mL–1, respectively). Plated cells were
grown in neural differentiation medium (NDM) composed of
neurobasal medium (Invitrogen) supplemented with 1% N2
(Invitrogen), 1% B27 (without Vitamin A, Invitrogen), 1%
Glutamax (Invitrogen), 1% NEAA (Invitrogen), plus BDNF,
GDNF and IGF-1 (Peprotech, all at a final concentration of
10 ng mL–1). Following NS final plating, postmitotic neurons
were developed within 10 days. Fully developed neurons
were observed 25 days post-plating.
RNA extraction and real-time RT-PCR
Cell samples of HDF2-iPSC and SC128were collected at four
stages during the neuronal differentiation, i.e., iPSC (D0), IA
(D6), NE (D18), and mature neuron (D50). RNA was ex-
tracted with TRIzol Reagent (Ambion, USA) according to
the manufacturer’s protocol. The first strand cDNA was syn-
thesized using 200 ng of RNA with Revert Aid First Strand
cDNA Synthesis Kit (Thermo, USA). Real-time reverse tran-
scription PCR (RT-PCR) was performed using ABI Stepone
Plus to detect the fluorescence of SYBR Green (TIAGEN,
Beijing). GAPDHwas used as internal control for ∆∆Ct anal-
ysis. The primers are listed in Table S2 in Supporting Infor-
mation.
Immunohistochemistry
Cells on coverslips were fixed in 4% paraformaldehyde in
PBS (HyClone, USA) and immunostained according to the
standard protocols. Samples were washed three times in
PBS before they were permeablized and blocked in PBS
(HyClone) with 5% normal goat serum (Yeasen, Shanghai,
4% BSA was used for goat polyclonal antibody), 0.3%
Triton X for 1 h at room temperature. They were incubated
with diluted primary antibodies overnight at 4°C: SOX2
(1:100, mouse monoclonal, Santa Cruz Biotechnology,
USA), NANOG (1:1,000, goat polyclonal, R&D Systems,
USA), SOX1 (1:100, goat polyclonal, R&D Systems), FMRP
(1:1,000, rabbit polyclonal, Abcam, UK), NESTIN (1:250,
mouse monoclonal, BD bioscience, USA), PAX6 (1:200,
mouse monoclonal, DSHB, USA), GFAP (1:500, mouse
monoclonal, Novus Biologicals, USA), MAP2 (1:1,000,
rabbit polyclonal, Chemicon, USA), and TUJ1 (1:1,000,
mouse monoclonal, Covance, USA). After three-time washes
in PBS (HyClone), they were incubated with appropriate
flurochrome-conjugated secondary antibodies (Cy2-conju-
gated 1:300, or Cy3-conjugated, 1:500; both from Jackson
Immunoresearch, West Grove, PA) for 2 h at room tem-
perature. Cells were mounted using Vectashield containing
4′,6-diamidino-2-phenylindole (DAPI; Vector Lab, USA)
and analyzed by luorescent microscope (Nikon eclipse Ti-S,
Japan and Leica TCS SPS, Germany).
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Library construction and RNA-seq
We constructed RNA-seq libraries following the protocol
described in Illumina TruSeqTM RNA Sample Preparation
Guide. Briefly, we started with 400 ng of total RNA. We
then purified poly-A containing mRNA molecules by poly-T
oligo-attached magnetic beads. After RT and complemen-
tary cDNA strand synthesis, we did end-repair and adapter
ligation. Finally we amplified the cDNA by 15-cycle PCR.
The concentration of the amplified product was determined
by Qubit Fluorometer (Invitrogen). Ten nmol of each sample
was sequenced according to the manufacturer’s instruction
with Illumin Hiseq 2000. Sequencing reads were mapped
to the hg19 genome using burrows-wheeler alignment tool
Tophat (Bowtie2).
Bioinformatics analysis
The raw reads were cleaned by removing adapter sequences,
reads containing poly-N and low-quality sequences (Q<20).
Clean reads were aligned to the reference genome (hg19)
using TopHat v2.0.13 (Kim et al., 2013) with default param-
eters, allowing no more than two mismatches. The statistics
of raw reads, mapped reads were summarized in Table S3 in
Supporting Information. For each transcript, fragment per
kilobase per million (RPKM) mapped reads were calculated
to evaluate the expression level. The differentially expressed
genes were identified by the tool Cuffdiff v1.3.0 (Trapnell
et al., 2012). A P-value of 0.05 and a log2 (fold-change)
of 1 were set as the threshold for significant differential
expression. Unsupervised clustering (k-means, k=7) was
applied to the log2 scaled fold change of SC128 vs. HDF.
Gene ontology (GO) enrichment analysis of differentially
expressed genes (DEGs) was performed by DAVID online
tool (http://david.abcc.ncifcrf.gov) (Huang da et al., 2009).
GO terms with P-value smaller than 0.01 were selected to
present. Up- and down-regulated DEGs at neuron stage
were selected to generate the biological function networks
by cytoscape application GeneMANIA (Warde-Farley et
al., 2010). The microarray data used for integrated analysis
were retrieved from the Gene Expression Omnibus (GEO)
(http://www.ncbi.nlm.nih.gov/geo/) with access number
GSE25542 (Pasca et al., 2011) and GSE62721 (Halevy et al.,
2015). RMA was performed to normalize probe signal. The
DEGs shared by both our data and the microarray data were
chosen for downstream analysis. Gene expression level in
between different samples and datasets was normalized by
“combat” function in Bioconductor SVA package to remove
batch effects. P-value of 0.01 and a log2 (fold-change) of 1
were set as the threshold for calling DEGs in the microarray
data.
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